nVerses Capital’s Opus Genetics IRD Stock Holding History

nVerses Capital’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28,564	Closed	-$130K	–	559
2026 Q1	$130K	Buy	+28,564	New	+$98.8K	0.12%	315

Other funds holding IRD

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

nVerses Capital's IRD Position: Q2 2026 in Review

nVerses Capital sold out of Opus Genetics (IRD) in Q2 2026, closing a stake of 28,564 shares — an estimated $130K sold.

nVerses Capital first reported a position in IRD in Q1 2026 and held it in 1 quarter. The position peaked at $130K in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

nVerses Capital reported no remaining Opus Genetics position as of Q2 2026 after selling out during the quarter.
nVerses Capital sold 28,564 Opus Genetics shares in Q2 2026, an estimated $130K.
nVerses Capital first reported a position in Opus Genetics in Q1 2026 and held it in 1 quarter.
nVerses Capital's Opus Genetics position peaked at $130K in Q1 2026.
103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.